Skip to main content

Ally Bridge Group — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

48
Companies
$4.7B
Total invested
$131.4M
Avg. check
17
Industries
Health Care 21Biotechnology 17Medical 10Medical Device 9Therapeutics 8Pharmaceutical 5+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 48
Ceribell
September 2022

Ceribell focuses on making electroencephalography accessible, efficient, and cost-effective.

Biotechnology · Mountain View$50.0M Series C
Ultivue
July 2024

Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing.

Biopharma · Cambridge$3.3M Venture - Series Unknown
Definium Therapeutics
June 2026

Definium Therapeutics provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.

Biotechnology · New York$805.0M Post-IPO Equity
Aeglea BioTherapeutics
June 2023

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.

Biotechnology · Austin$210.0M Post-IPO Equity
Alzheon
June 2024

Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.

Biotechnology · Framingham$100.0M Series E
Context Therapeutics
May 2024

Context Therapeutics is a clinical-stage biopharmaceutical company.

Biotechnology · Philadelphia$100.0M Post-IPO Equity
Whitehawk Therapeutics
May 2026

Whitehawk Therapeutics, a clinical-stage oncology therapeutics firm, applies cutting-edge technologies to well-established tumor biology.

Biopharma · Pacific Palisades$87.5M Post-IPO Equity
Endeavor BioMedicines
April 2024

Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.

Biotechnology · Solana Beach$132.5M Series C
Calyxo
April 2026

Calyxo is a medical device company that improves kidney stone treatment through specialized urology technologies.

Health Care · Pleasanton$40.0M Series F
Quantum Surgical
March 2024

Quantum Surgical mission is to democratize minimally invasive liver cancer treatment

Health Care · Montpellier$32.4M Debt Financing
Imperative Care
March 2026

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

Health Care · Campbell$100.0M Convertible Note
MedAvail
March 2023

MedAvail focuses on the discovery, development, and commercialization of advanced nutrition products.

Biotechnology · Mississauga$16.0M Post-IPO Equity
Perspective Therapeutics
February 2026

Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.

Health Care · Seattle$175.0M Post-IPO Equity
VitalConnect
February 2025

VitalConnect offers wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations.

Biotechnology · San Jose$100.0M Venture - Series Unknown
Galvanize Therapeutics
September 2025

Galvanize is a biomedical platform company that provides therapeutic products and services to deliver healthcare solutions.

Health Care · San Carlos$100.0M Series C
SetPoint Medical
August 2025

SetPoint Medical provides a device-based therapy for rheumatoid arthritis.

Biotechnology · Valencia$115.0M Series D
Epicrispr Biotechnologies
March 2025

Epic Bio's strength is a relentless focus on ushering in a new era of gene regulation.

Biotechnology · South San Francisco$68.0M Series B
Skye Bioscience
January 2024

Skye Bioscience is a pharmaceutical company developing new therapeutic outcomes for diseases.

Biotechnology · San Diego$50.3M Post-IPO Equity
Biobeat
December 2025

Biobeat is a med-tech company that develops remote patient monitoring and data collection tool.

Biotechnology · Boca Raton$50.0M Series B
Kestra Medical Technologies, Inc.
December 2025

Kestra Medical Technologies offers wearable medical devices which collects, store, and communicate patients vital performance data.

Health Care · Kirkland$138.0M Post-IPO Equity
Aerin Medical
January 2025

Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing.

Biotechnology · Mountain View$32.5M Undisclosed
Kandu Health
January 2026

Kandu Health is a tech-enabled healthcare company that provides stroke recovery training, stroke detection research, and education services.

Education · CampbellVenture - Series Unknown
Elligo Health Research
October 2023

Elligo Health Research brings clinical research to physician practices and accelerate the development of medical device and therapies.

Biotechnology · Austin$25.0M Debt Financing
MindMed
October 2025

MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.

Biotechnology · New York$225.0M Post Ipo Equity

Where Ally Bridge Group invests

Health Care21
Biotechnology17
Medical10
Medical Device9
Therapeutics8
Pharmaceutical5

About Ally Bridge Group's portfolio

How many companies has Ally Bridge Group invested in?

Ally Bridge Group has invested in 48 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Ally Bridge Group invest in?

Ally Bridge Group's top investment sectors include Health Care, Biotechnology, Medical, Medical Device, Therapeutics. The firm invests across 17 different industry categories.

What is Ally Bridge Group's largest investment?

Among tracked funding rounds, Definium Therapeutics received $805.0M in a Post-IPO Equity round. Ally Bridge Group's total known invested capital is $4.7B.

What is the average investment size for Ally Bridge Group?

Ally Bridge Group's average investment size is $131.4M across its portfolio of 48 companies.

What are Ally Bridge Group's most recent investments?

Recent Ally Bridge Group portfolio additions include Ceribell, Ultivue, Definium Therapeutics, Aeglea BioTherapeutics, Alzheon. These companies were founded in 2020 or later.

Reach the founders behind these 48 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →